FOXO-targeting compounds
FOXO-targeting compounds has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Jan 12, 2026: “FOXO: a key target in regulating aging and age-related diseases”.
1 paper studies it1 findingUpdated
See all 1 papers on FOXO-targeting compounds
What did studies of FOXO-targeting compounds find?
1Studies of FOXO-targeting compounds measured one outcome, metabolic disease.
Metabolic disease
downin reviews1
1 study
Metabolic disease
downin reviews1
FOXO-targeting compounds decrease metabolic disease.
“These FOXO-targeting compounds demonstrate great potential in improving metabolic disorders and delaying the onset of aging phenotypes.”
Review
FOXO: a key target in regulating aging and age-related diseases
Biogerontology